Autologous serum eye drops for ocular surface disorders- a clinical study
Abstract
Introduction: Tears have antimicrobial, nourishing, mechanical and optical properties. Several tear factors that have been identified to be, of importance in the maintenance of normal corneal and conjunctiva epithelium. A lack of these factors results in severe ocular surface disorders. Autologous serum in the form of eye drops has been reported as an effective treatment for severe ocular surface disorders. The present study was designed to determine the efficacy and safety of autologous serum application in various ocular surface disorders.
Methods: This is a prospective case analysis of 30 eyes of 18 patients between June 2009 & November 2010. The following tests were performed: Schirmer I, Basic secretion test, Tear film Breakup time, Fluorescein staining, Rose Bengal Staining. 20% concentration of Serum eye drop was used for 30 days and no other tear substitutes were prescribed to patients while during treatment.
Results: After one month treatment marked improvement was observed - 19 eyes in Schirmer I, 18 eyes in Basic tear secretion, 23 eyes in tear film Break up time, 21 eyes in Fluorescein staining pattern and 29 eye in Rose Bengal staining pattern.
Conclusion: It was observed that Hypovitaminosis A and Neurotrophic keratitis showed 100% improvement, kerato conjunctivitis sicca, sjogren's syndrome, persistent epithelial defect, Recurrent erosion syndrome, Marginal corneal ulcer also showed excellent results but Stevens - Johnson syndrome showed very poor response to treatment.
Downloads
References
2. Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004 Nov;88(11):1467-74. [PubMed]
3. Tsubotak, GotoE, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren’s syndrome. Br. J. ophthalmology 1999;83(4):390-5. [PubMed]
4. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with Keratoconjunctivitis sicca. Arthritis Rheum. 1984;27(4):459-61. [PubMed]
5. John E, Sutphin Jr. External disease and cornea. San Francisco,USA: American Academy of Ophthalmology; 2005.p53-54. [PubMed]
6. Abelson M, Ousler G, Nally L. Alternate reference values for tear film break-up time in normal and dry eye populations. Adv Exp Med Biol 2002;506 (Part B):1121-1125. [PubMed]
7. Korb D, Finnemare V, Herman J. A New method for fluorescein breakup time IOVS 1998;40.
8. Lemp MA. Report of the National Eye institute, Industry workshop on clinical trial in dry eye CLAO J. 1995 Oct;21(4):221-32. [PubMed]
9. Van Bijsterveld OP. Diagnostic tests in the sicca syndrome. Arch Ophthalmol 1969;82(1):10-14. [PubMed]
10. Quinto GG, Campos M, Behrens A. Autologous serum for ocular surface diseases. Arq Bras Oftalmol 2008;71(6 Supl):47-54. [PubMed]
11. Rocha EM, Pelegrino FS, de Paiva CS, Vigorito AC, de Souza CA. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant. 2000;25(10):1101-3. [PubMed]
12. Tsubota K, Satake Y, Ohyama M, Toda I, Takano Y, Ono M et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome. Am J Ophthalmol. 2006;122(1):38-52.
13. Ferreira de Souza R, Kruse FE, Seitz B. Autologes Serum bei sonst therapieresistenten Hornhautepitheldefekten—Prospektive Studie an den ersten 70 Augen.Klin Monatsbl Augenheilkd 2001;218(11):720–6.
14. Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20(8):802-6. [PubMed]
15. Takamura E , Shiozaki K, Hata H, et al. Efficacy of autologous serum treatment in patients with severe dry eye. In: Sullivan DA, ed. Lacrimal gland, tear film, and dry eye syndromes 3. Amsterdam: Kluwer Academic/Plenum Publishers, 2002:1247–50.
16. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2003 Apr;31(7):579-83. [PubMed]
17. Del Castillo JM, de la Casa JM, Sardiña RC, Fernández RM, Feijoo JG, Gómez AC et al. Treatment of recurrent corneal erosions using autologous serum. Cornea. 2002;21(8):781-3. [PubMed]
18. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea. 2001;20(8):807-10. [PubMed]
19. Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynolds A, Bridges LR etal. Comparison of autologous serum eye drops with conventional therapy in a randomized controlled crossover trial for ocular surface disease. Br J Ophthalmol.2004;88(5):647-52.
20. Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001;85(10):1188-97. [PubMed]
21. Lagnado R, King AJ, Donald F, Dua HS. A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. Br J Ophthalmol. 2004;88(4):464-5.
OAI - Open Archives Initiative
